{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:53:27Z","timestamp":1791827607415,"version":"4.3.4"},"reference-count":34,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"unspecified","delay-in-days":103,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,9,19]]},"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1136\/lupus-2026-002168","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:40:27Z","timestamp":1791826827000},"page":"e002168","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Suboptimal attainment of SLE treat-to-target goals based on persistently high physician global assessment: an analysis of German SPOCS patients"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-8375","authenticated-orcid":false,"given":"Martin","family":"Aringer","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine III, TUD Dresden University of Technology Faculty of Medicine Carl Gustav Carus, Dresden, SN, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-5680","authenticated-orcid":false,"given":"Peter","family":"Korsten","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, St Josef-Stift Sendenhorst, Sendenhorst, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, BE, Germany"},{"name":"DRFZ, Berlin, BE, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Hiepe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, BE, Germany"},{"name":"DRFZ, Berlin, BE, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmalzing","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Rheumatology and Clinical Immunology, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lioba","family":"Pieterse","sequence":"additional","affiliation":[{"name":"Private Practice for Nephrology, Rheumatology, and Hypertension, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Giefer","sequence":"additional","affiliation":[{"name":"Medical Affairs Immunology, AstraZeneca GmbH, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Brandenburg","sequence":"additional","affiliation":[{"name":"Medical Affairs Immunology, AstraZeneca GmbH, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9131-4563","authenticated-orcid":false,"given":"Bo","family":"Ding","sequence":"additional","affiliation":[{"name":"AstraZeneca Sweden, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-8381","authenticated-orcid":false,"given":"Julia","family":"Weinmann-Menke","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Johannes Gutenberg University Hospital Mainz, Mainz, Germany"},{"name":"Nephrology, University Hospital Heidelberg, Heidelberg, BW, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026101210401398000_13.2.e002168.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223741"},{"key":"2026101210401398000_13.2.e002168.2","doi-asserted-by":"crossref","first-page":"102801","DOI":"10.1016\/j.cpcardiol.2024.102801","article-title":"Trends and disparities in cardiovascular deaths in systemic lupus erythematosus: A population-based retrospective study in the United States from 1999 to 2020","volume":"49","author":"Ahmed","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2026101210401398000_13.2.e002168.3","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001383","article-title":"Association of race and ethnicity with mortality in adults with SLE: a systematic literature review and meta-analysis","volume":"12","author":"Patel","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026101210401398000_13.2.e002168.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16676-2"},{"key":"2026101210401398000_13.2.e002168.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123919"},{"key":"2026101210401398000_13.2.e002168.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026101210401398000_13.2.e002168.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026101210401398000_13.2.e002168.8","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026101210401398000_13.2.e002168.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2026101210401398000_13.2.e002168.10","unstructured":"Franklyn K , Lau CS , Navarra SV , et al . Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). AnnRheumDis 2015."},{"key":"2026101210401398000_13.2.e002168.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036563","article-title":"Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature","volume":"10","author":"Hammond","year":"2020","journal-title":"BMJ Open"},{"key":"2026101210401398000_13.2.e002168.12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026101210401398000_13.2.e002168.13","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001336","article-title":"Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)","volume":"12","author":"Aringer","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026101210401398000_13.2.e002168.14","doi-asserted-by":"crossref","unstructured":"Morand EF , Furie R , Aringer M , et al . Disease progression in patients with systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS). Rheumatology (Oxford) 2026;65. doi:10.1093\/rheumatology\/keaf599","DOI":"10.1093\/rheumatology\/keaf599"},{"key":"2026101210401398000_13.2.e002168.15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/jcm10163754","article-title":"Patient-Reported Outcomes for Quality of Life in SLE: Essential in Clinical Trials and Ready for Routine Care","volume":"10","author":"Nguyen","year":"2021","journal-title":"J Clin Med"},{"key":"2026101210401398000_13.2.e002168.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.24165"},{"key":"2026101210401398000_13.2.e002168.17","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/acr.22372","article-title":"Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a Delphi exercise of experts and a literature review","volume":"66","author":"Leuchten","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026101210401398000_13.2.e002168.18","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221090885"},{"key":"2026101210401398000_13.2.e002168.19","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001032","article-title":"Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature","volume":"10","author":"Arnaud","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026101210401398000_13.2.e002168.20","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001597","article-title":"Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data","volume":"12","author":"Rua-Figueroa","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026101210401398000_13.2.e002168.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2026101210401398000_13.2.e002168.22","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2026101210401398000_13.2.e002168.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2026101210401398000_13.2.e002168.24","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026101210401398000_13.2.e002168.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2026101210401398000_13.2.e002168.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3936"},{"key":"2026101210401398000_13.2.e002168.27","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2026-002054","article-title":"Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort","volume":"13","author":"Lozano-Rivas","year":"2026","journal-title":"Lupus Sci Med"},{"key":"2026101210401398000_13.2.e002168.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"2026101210401398000_13.2.e002168.29","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag045","article-title":"Treating-to-target: remission and low disease activity in systemic lupus erythematosus versus rheumatoid arthritis","volume":"65","author":"H\u00fcther","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"2026101210401398000_13.2.e002168.30","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000861","article-title":"Molecular endotypes of type 1 and type 2 SLE","volume":"10","author":"Robl","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026101210401398000_13.2.e002168.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209519"},{"key":"2026101210401398000_13.2.e002168.32","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAD460"},{"key":"2026101210401398000_13.2.e002168.33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002395","article-title":"Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus","volume":"8","author":"Mertz","year":"2022","journal-title":"RMD Open"},{"key":"2026101210401398000_13.2.e002168.34","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000469","article-title":"Living with systemic lupus erythematosus in 2020: a European patient survey","volume":"8","author":"Cornet","year":"2021","journal-title":"Lupus Sci Med"}],"container-title":["Lupus Science & Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-002168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:40:31Z","timestamp":1791826831000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,10,12]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/lupus-2026-002168"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-002168","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}